

FORWARD-LOOKING STATEMENTS

Statements in this presentation about future expectations, plans, and prospects, as well as any other statements regarding matters that are not historical facts, may constitute 'forward-looking statements.' The words 'anticipate,' 'believe,' 'continue,' 'could,' 'estimate,' 'expect,' 'intend,' 'may,' 'plan,' 'potential,' 'predict,' 'project,' 'should,' 'target,' 'will,' 'would' and similar expressions are intended to identify forwardlooking statements, although not all forward-looking statements contain these identifying words. Investors should read the risk factors set forth in our Form 10-K for the year ended December 31, 2024, and in our registration statement on Form S-1 and other periodic reports filed with the Securities and Exchange Commission. Actual results may differ materially from those indicated by such forwardlooking statements as a result of various important factors, including the uncertainties related to market conditions. Any forward-looking statements contained in this presentation speak only as of the date hereof, and Syra Health specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events, or otherwise.





Headquartered in Carmel, Indiana




Incorporated in 2020



Active Contracts in 23 + States

Company Profile





Women-Led, Minority Certified Business



Publicly traded on OTCQB: SYRA



~100 Employees



Operates as 3 Business Units

Introduction to Syra Health

A mission-driven healthcare technology organization transforming

mental and population health.



Impacted

2 million

lives across 22 states in the U.S.

2023: Successful Nasdaq IPO, Boosting Our Visibility

2025 and Beyond:

through Syrenity's

Expansion and

Diversification

Propelling Exponential

Growth

Revenue

2022: Strategic **Execution and Growth Acceleration**

2020-2021

Building a Strong Foundation

Primary Business Sectors



Behavioral & Mental Health



Population Health



Healthcare Workforce

Learn About Us - Syra Health Video



Syra Health Addresses 3 High-Growth Markets

			1	-	-	٠.	
		٠.	•	-	٠,	•	
	ì	١((.	C	Ž))	ŀ
		١,	↘	ς	ゝ	U.	
			7.		٠.	۲.	٠
	•	1	Δ	ı. i	·P	Ŋ	٠.
		2	_	_	7	≺	S
•	. 7	`	٠.	-	٠.	ب	,-
						. 1	

Behavioral Health

\$110B (2024) \rightarrow \$166.91B (2033)

CAGR: 2.1%



Population Health

 $$29B (2023) \rightarrow $113B (2033)$

CAGR: 21.3%



\$24B (2023) -> \$43B (2033)

CAGR: 5.71%



Behavioral Health: Empowering Mental Health through Innovation

Key Segments of Syra's impact

Digital Mental Health Tools: Al-driven platforms providing personalized mental health assessments, real-time monitoring, and therapeutic interventions.

Employee Assistance Programs (EAPs): Supporting organizations with proactive mental health solutions to improve workplace well-being and productivity.

Student Health and Academic Partnerships: Collaborating with universities to provide tailored mental health solutions for students, addressing rising rates of anxiety and depression while improving academic and retention outcomes.

Market Penetration and Growth: Universities, employers, public health agencies, and direct to consumers.

Market Size

\$166B by 2033, CAGR: 2.1%.

Market Drivers



Increasing mental health awareness.



Employer-driven wellness investments (+20% annually).



Federal and state funding for mental health services and initiatives.

Syrenity: Addressing Unmet Needs in Behavioral and Mental Health



Differentiators

- Scientifically-based digital assessments for common mental health conditions such as anxiety, anger, and insomnia.
- Al-driven user engagement for tracking progress.
- Real-time alerts for at-risk users.



Impact Metrics

Preliminary results from a sixweek clinical research study showed trends toward lowering depression symptoms among Syrenity users when compared to those without access to the app, among other indicators of improvement.



Growth Potential

 Expanding into Statewide and Federal mental health initiatives – while tapping into universities, EAPs, and direct to consumer activities.




(\$12.99 per month per user on app stores; B2B has a scaling price model based on users and implementation charges)


Syrenity Video: The Future of Science-Backed Al-Driven Mental Health Solutions




Syrenity is Dually-Focused on Prevention and Intervention









Population Health: Addressing Health Equity, Wellness, and Prevention

Key Segments of Syra's impact

Data-Driven Solutions: Predictive, causal and spatial analytics.

Tech & Innovation: Telehealth, Al, and dashboard reporting.

Public and Organizational Health Policies: Recommendations, grant writing, and epidemiological studies. Value-Based Care Services: Care & chronic disease management, community engagement, and health equity initiatives.

Preventive Wellness: Early intervention, reducing costly treatments.

Health Education & Training Services:

Provide knowledge and skills needed to improve health outcomes for entire populations.

Market Penetration and Growth: Government agencies, private insurers, and healthcare providers.

Market Size

\$113B by 2033, CAGR: 21.3%.

Market Drivers



Shift to value-based care models.



Government initiatives: Medicare Advantage, ACA funding.



Rising chronic disease prevalence.

Key Government Contracts in Population Health Across the U.S.

Data Analytics and Advisory Services:



- Indiana State Epidemiological Outcomes Workgroup (SEOW) 2021 to 2025: Manage the workgroup and data analytics
- Epidemiological and Biostatistical Analytical services for Shelby County, TN 2024 to 2026

Assessments and Evaluation:



 City of San Antonio Public Health Department, TX – Evaluation of CDC REACH Healthy Neighborhoods program – 2023 to 2028

 Minnesota Division of Human Services / FQHC – Implement CLAS standards using evidence-based practices, training, and performing evaluations – 2023 to 2025

Data collection:



Indiana Medicaid / HHW and HIP / HEDIS Data collection – 2024 to 2028

Health Education & Training:

- Indiana FSSA training contract for professionals who deliver care to Indiana residents at home or in a community-based setting – 2024 to 2028
- Midwest-based university training contract to develop prevention-focused virtual training modules in behavioral health – 2025



Ethical Al: Advancing Trust and Responsibility in Healthcare

Ensuring Responsible AI Usage

At Syra Health, we emphasize that AI in healthcare must prioritize trust, privacy, and fairness. Our proprietary **Syra Guardrails** technology ensures AI-powered interactions are safe, transparent, and ethical.

Core Principles of Ethical AI with Syra Guardrails:



Protecting Privacy

Stringent data protocols safeguard sensitive patient information.



Transparency in AI

Syra enables clear explanations of Al-generated responses, enhancing accountability.



Bias-Free Engagement

Built to eliminate bias, ensuring equitable care for all.



Fostering Trust

Ethical practices that promote confidence in Al-driven healthcare solutions.





Conversational Al-powered chatbot designed as a **companion** —helping users feel connected, engaged, and empowered in their healthcare experience.







Reduces support calls by at least 15%




Increases member/user engagement



Improves access to care and information



Customizable for various member population demographics





Meets CLAS Standards

Respects and **responds** to personal health needs and preferences

How may we help you?



Healthcare Workforce: Delivering Scalability and Dependability

Key Segments of Syra's impact

Scalable Staffing Solutions: Al-driven recruitment and role matching based on skills and availability.

Workforce Development & Training: Tailored training programs to enhance skills, especially in emerging healthcare fields.

Temporary and Contract Staffing

Flexible staffing solutions to address shortages and fluctuating demand.

Market Penetration and Growth: Federal contracts with agencies like HHS, VA, and NIH; including leveraging current vehicles DHA - MQS2-NG, ORR GSA, State Government Partnerships, Private Sector

Market Drivers



Aging population and increased chronic disease prevalence




Expanding healthcare facilities and services.



Labor shortages and increasing patient care demands


Syra Health's Financial Outlook: Charting a Path to Sustainable Growth and Innovation



High-Margin Business Units Driving Revenue Diversification Year-over-Year



Q4 2024 Year-over-Year Revenue Comparison



Operational and Organizational Restructuring Drives Q4 2024 Year-over-year Performance Gains



Revenue increased 14%



(0.16)
per share to
(0.05)



Gross margin variation from 33.0% to 22.7%



Operational expenses decreased 39%



Net loss decreased 49%

Syra Health's Differentiation: Advanced Technology, Comprehensive Services, and Strong Market Position

- Government Contract Experience
- Specialized Mental Health Expertise
- Comprehensive Service Portfolio
- Customized and Scalable Solutions:
- Al and Data-Driven Solutions
- Strategic Partnerships
- Data Security and Trust
- Commitment to Health Equity



Exciting Milestones Ahead: Syra Health's Roadmap for 2025 and Beyond



Scaling of new and renewed government contracts

Revenue generation through new contracts secured in 2024, while continuing to renew existing contracts across multiple states.

Secure **long-term revenue** streams, solidifying presence in the healthcare market.



Expansion of Syrenity

US market penetration, schools & universities, large employers, EAP programs, direct to consumers. Global expansion to underserved markets, particularly in lower-to-middle-income regions.



Advancing Strategic Partnerships

Strengthening collaborations with government agencies, academia, and private healthcare providers to gain competitive edge.

Capitalization Table

Class A Common Stock	11,312,544 shares		
Class B Common Stock	600,000 ⁽¹⁾ x 10 Class A shares		
Total Outstanding Shares	17, 312,544 shares		
Options	To purchase 223,599 shares of Class A common stock		
Warrants from IPO	To purchase 1,629,561 shares of Class A common stock		
Warrants from September 2024	To purchase 6,566,406 shares of Class A common stock		
Capital Raise	Of Class A Common stock		
Cash	\$2.4 M (As of December 31, 2024)		
Debt	No long-term debt		

⁽¹⁾Every Class B share is entitled to 16.5 votes per share.

Syra Health Board Of Directors



Deepika Vuppalanchi, PhD

- Chair, CEO & Co-Founder of Syra Health
- Dr. Vuppalanchi has more than 10 years of healthcare and medical research experience.
- She holds a PhD and Master's degree in Molecular Biology and Genetics from the University of Delaware.
- She previously served as senior medical director at Precision For Value, and as medical education director at Symbiotix and DWA Healthcare Communications.



Priya Prasad, MBA


- Chief Operating Officer & Chief Financial Officer of Syra Health
- Priya has nearly 20 years of experience in finance and operations.
- She has served as president of STLogics for nearly 20 years and is a board member for RADcube and Skill Demand Energy.
- She holds an MBA from the University of Massachusetts, Boston, and a Master of Science degree from Bangalore University.



Sherron Rogers

- Ms. Rogers has served as Chief Financial Officer of Johns Hopkins All Children's Hospital, since March 2022.
- Previously, Ms. Rogers served as Chief Financial Officer and Chief Strategy Officer of Eskenazi Health. She was with Eskenazi Health from 2016-2022 leading growth and improvement initiatives.
- She spent over a decade at Indiana University Health in leadership roles.
- Prior to healthcare, Ms. Rogers was in manufacturing at Cummins, Inc. focused on global and administrative process improvement.

Syra Health Board Of Directors



Andrew M. Dahlem

- Dr. Dahlem has served as Senior Research Professor of Medicine at Indiana University School of Medicine, since 2018.
- Dr. Dahlem is Co-founder and Advisor to Gate Neurosciences, and President of Dr. Dahlem Consulting LLC, advising on the discovery and development of novel therapeutics for academia, biotech, and the pharmaceutical industry.
- Dr. Dahlem previously spent 30 years at Lilly, including as Chief Operating Officer of Lilly Research Laboratories.



Vijayapal R. Reddy

- Dr. Reddy has served as an Advisor and Director of VIPRA, LLC, a consulting company, since August 2017.
- From 2007 to 2017, Dr. Reddy served as a Senior Researcher Advisor/Executive Director of Lilly Research Laboratories, where he led nonclinical safety and regulatory assessments of several cross-functional programs at different stages of development.



Ketan Paranjape

- Dr. Paranjape is Chief Operating Officer and Vice President of Enterprise Imaging for Optum.
- Previously, Dr. Paranjape served in various leadership roles at Roche Diagnostics, including as Vice President of Information Solutions, Vice President of Commercial Business Operations, and Vice President of Business Intelligence and Analytics.



Avutu S. Reddy

- Dr. Avutu has over 27 years of corporate leadership experience in strategy & innovation. Since joining Dow AgroSciences, he has held multiple leadership roles, managing project budgets, pipeline financial assessments and due diligence for M&As. He currently serves as the Scientific Strategic and Emerging Business Intelligence Leader at Corteva Agriscience.
- Before transitioning to industry, Dr. Avutu was an Asst. Professor & Director of Genomics at Texas A&M University. He has authored over 50 publications and holds over 30 patents.



For More Information

Contact



For Media: Christine Drury, Syra Health Christined@syrahealth.com 463-345-5180



For Investor Relations: Corbin Woodhull, Hayden IR corbin@haydenir.com 914-787-0479



Capital Raise (September 2024)

Offering Size	3,203,125 Units ⁽¹⁾		
Series A Warrants	To purchase 3,203,125 shares of Class A common stock		
Series B Warrants	To purchase 3,203,125 shares of Class A common stock		
Underwriter Warrants	To purchase 160,157 shares of Class A common stock		
Price	\$0.64 per Unit		
Gross Proceeds	\$2.1 M		

⁽¹⁾ Each Unit consisted of one share of Class A common stock, one Series A warrant, and one Series B warrant. Series A warrants expire on the 18th month anniversary of the issuance date. Series B warrants expire on the fifth anniversary of the issuance date. The Series warrants have an exercise price of \$0.64/share. The Underwriter warrants have an exercise price of \$0.80/share.